

In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.

Jesse W. Wotring¹, Sean M. McCarty¹, Khadija Shafiq¹, Charles J. Zhang¹, Theophilus Nguyen², Sophia R. Meyer¹, Reid Fursmidt², Carmen Mirabelli³, Martin C. Clasby¹, Christiane E. Wobus³, Matthew J. O'Meara⁴, Jonathan Z. Sexton^{1,2,5 *}

¹ Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.

²Department of Internal Medicine, Gastroenterology and Hepatology, Michigan Medicine at the University of Michigan, Ann Arbor, MI, 48109, USA.

³Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.

⁴Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.

⁵U-M Center for Drug Repurposing, University of Michigan, Ann Arbor, MI, 48109, USA.

* Corresponding author: jzsexton@med.umich.edu

Abstract

Niclosamide, an FDA-approved oral anthelmintic drug, has broad biological activity including anticancer, antibacterial, and antiviral properties. Niclosamide has also been identified as a potent inhibitor of SARS-CoV-2 infection *in vitro*, generating interest in its use for the treatment or prevention of COVID-19. Unfortunately, there are several potential issues with using niclosamide for COVID-19, including low bioavailability, significant polypharmacology, high cellular toxicity, and unknown efficacy against emerging SARS-CoV-2 variants of concern. In this study, we used high-content imaging-based immunofluorescence assays in two different cell models to assess these limitations and evaluate the potential for using niclosamide as a COVID-19 antiviral. We show that despite promising preliminary reports, the antiviral efficacy of niclosamide overlaps with its cytotoxicity giving it a poor *in vitro* selectivity index for anti-SARS-CoV-2 inhibition. We also show that niclosamide has significantly variable potency against the different SARS-CoV-2 variants of concern and is most potent against variants with enhanced cell-to-cell spread including B.1.1.7. Finally, we report the activity of 33 niclosamide analogs, several of which have reduced cytotoxicity and increased potency relative to niclosamide. A preliminary structure-activity relationship analysis reveals dependence on a protonophore for antiviral efficacy, which implicates nonspecific endolysosomal neutralization as a dominant mechanism of action. Further single-cell morphological profiling suggests niclosamide also inhibits viral entry and cell-to-cell spread by syncytia. Altogether, our results suggest that niclosamide is not an ideal candidate for the treatment of COVID-19, but that there is potential for developing improved analogs with higher clinical translational potential in the future.

Key Words: Niclosamide, SARS-CoV-2, COVID-19, Polypharmacology, Drug Repurposing

Importance

There is still an urgent need for effective anti-SARS-CoV-2 therapeutics due to waning vaccine efficacy, the emergence of variants of concern, and limited efficacy of existing antivirals. One potential therapeutic option is niclosamide, an FDA approved anthelmintic compound that has shown promising anti-SARS-CoV-2 activity in cell-based assays. Unfortunately, there are significant barriers for the clinical utility of niclosamide as a COVID-19 therapeutic. Our work emphasizes these limitations by showing that niclosamide has high cytotoxicity at antiviral concentrations, variable potency against variants of concern, and significant polypharmacology as a result of its activity as a nonspecific protonophore. Some of these clinical limitations can be mitigated, however, through structural modifications to the niclosamide scaffold, which we demonstrate through a preliminary structure activity relationship analysis. Overall, we show that niclosamide is not a suitable candidate for the treatment of COVID-19, but that structural analogs with improved drug properties may have higher clinical-translational potential.

Introduction

Since it emerged as a novel betacoronavirus in late 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a global pandemic¹. COVID-19, the disease caused by SARS-CoV-2 infection, presents as varying symptoms with different degrees of severity ranging from dry cough and difficulty breathing to acute cardiac injury and refractory pulmonary failure^{2,3}. As of April 2022, COVID-19 has caused the death of over six million individuals worldwide⁴ and this death toll continues to increase as new SARS-CoV-2 Variants of Concern (VOCs) emerge with enhanced transmissibility and increased adaptive immune escape⁵.

The deadly impact of COVID-19 has created a need to identify potential antiviral treatments for SARS-CoV-2 infection. This has culminated in the development and FDA-authorization/approval of several vaccines⁶, and three small-molecule antiviral medications including remdesivir⁷, molnupiravir⁸, and Paxlovid⁹. Unfortunately, because of limited worldwide vaccine availability¹⁰, the modest clinical efficacy of existing antivirals^{8,9,11,12}, and the potential resistance of SARS-CoV-2 variants^{13,14}, additional therapeutics are urgently needed to help stop the spread of the virus.

A promising strategy for identifying new therapies with the potential for rapid deployment is drug repurposing, whereby compounds with already established safety profiles and robust supply chains are used to treat other diseases¹⁵. Since the start of the pandemic, several large-scale drug repurposing screens have been conducted^{16–20} and have identified many different potential candidates for the treatment of COVID-19. One of the repurposed drugs, which had potent anti-SARS-CoV-2 efficacy *in vitro*, was the oral anthelmintic compound niclosamide^{17,20}.

Traditionally used to treat tapeworm infection, niclosamide has been often repurposed in treating a wide range of diseases including several cancers, bacterial infections, viral infections, type 2 diabetes, non-alcoholic fatty liver disease, and rheumatoid arthritis²¹. This range of potential uses is due to the significant polypharmacology of niclosamide, which is known to act on many different biological targets and is a modulator of the Wnt/b-catenin, mTOR and JAK/STAT3 signaling pathways among others²¹. Niclosamide is also a weakly acidic lipophilic protonophore that can disrupt pH gradients by shuttling protons across lipid membranes²² including mitochondria and lysosomes/endosomes. This physiochemical property is responsible for its activity as a mitochondrial uncoupler²³ and contributes to its broad activity against viruses, many of which rely on endosomal-cytoplasmic pH gradients in their life cycle²⁴.

Niclosamide was also previously identified as a potential antiviral for the related coronavirus SARS-CoV, where it was shown to inhibit viral replication *in vitro* with low micromolar potency²⁵. The mechanism of action (MOA) for niclosamide against SARS-CoV-2 may be more complex and multimodal than for SARS-CoV. Niclosamide has been shown to inhibit SARS-CoV-2 endocytosis mediated entry²⁶, block viral replication by promoting cellular autophagy²⁷, and disrupt spike (S) protein-mediated syncytia formation via inhibition of the host cell calcium-dependent scramblase TMEM16F²⁸. Given the polypharmacology of niclosamide, it is likely that there are additional factors that contribute to its overall efficacy and complicate its MOA. The degree to which each of these MOAs plays a role in the antiviral efficacy of niclosamide against SARS-CoV-2 is unclear.

While niclosamide was clinically effective as an anthelmintic drug, it has substantial limitations for use as a COVID-19 antiviral including its low oral bioavailability (<10%) and poor water solubility^{29,30}. Oral administration of niclosamide at 5 mg/kg in rats reaches a maximal serum concentration (C_{max}) of only 354 ± 152 ng/mL³¹. As a result, the concentration of niclosamide in the lungs would likely be too low to achieve therapeutic effect. Another limitation exists in that polypharmacology is generally associated with increased adverse effects for repurposed drugs³². Finally, the toxicity of niclosamide is a major concern as it has been previously repurposed as a broad anti-cancer agent and has shown significant cytotoxic/cytostatic effects *in vitro*^{33,34}. A better understanding of the anti-SARS-CoV-2 mechanism of action for niclosamide, including potential toxicity and activity against emerging variants of concern (VOC), is needed to effectively evaluate its clinical potential.

The goal of this study was to expand upon the understanding of niclosamide anti-SARS-CoV-2 activity and its potential as a clinical therapeutic using high content fluorescence imaging and

analysis. Herein, we reveal some of the mechanistic and cell morphological characteristics of niclosamide activity, including an analysis of its cellular toxicity after long-term exposure to a therapeutic antiviral dose. Additionally, we investigate niclosamide antiviral activity against SARS-CoV-2 viral VOCs. We hypothesized that because the fusogenicity amongst SARS-CoV-2 variants is known to be different^{35–37}, the potency/efficacy of niclosamide may also vary between strains. Here we reveal the potency of niclosamide against several variants including WA1 (wildtype), B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta). Lastly, we report the *in vitro* results of a structure-activity relationship (SAR) campaign of 33 niclosamide analogs against SARS-CoV-2 in two different cell lines (VeroE6 and H1437). We used the results from this SAR campaign to reveal additional mechanistic details for niclosamide, and aid with the identification of structural analogs with reduced cellular toxicity. Altogether, our results suggest that niclosamide itself is not a suitable candidate for the treatment of COVID-19, yet there is potential for developing analogs with improved properties for future clinical use.

Results

Niclosamide has a poor selectivity index

One major concern regarding the utility of niclosamide as a COVID-19 antiviral is its cytotoxicity in comparison with its antiviral efficacy. Here, we aimed to determine the selectivity index (SI) of niclosamide *in vitro* against SARS-CoV-2 in two different cell models for infection, VeroE6 and the human lung adenocarcinoma cell line H1437. To assess compound-related toxicity, we evaluated the effects of niclosamide on cells after 72 hours of compound exposure. We designed and optimized two separate high-content fluorescence imaging assays in 384-well plate format using the different cell lines and measured cell viability and viral inhibition concurrently. In both assays, we used the detection of viral nucleocapsid (N) protein as

a direct marker for SARS-CoV-2 infection and cell count per well as an indicator of cell viability. As summarized in the **Figure 1A** workflow, VeroE6 or H1437 cells were preincubated with a 10-point 2-fold dilution series of niclosamide (N=10 replicates per condition) for 24 hours and then infected with the SARS-CoV-2 B.1.1.7 variant for an additional 48 hours post-infection (p.i.). Following infection, cells were fixed, permeabilized, and stained to identify nuclei and viral N protein. Assay plates were imaged at 10X magnification using a CX5 high content imaging platform (N=9 fields captured per well) and processed using the image segmentation and analysis software CellProfiler. Data from the CellProfiler output were used to determine percent infection and percent viability. Infection data were normalized to the average well-level % N positive for infected controls (mock) in each cell line (**Supplementary Figure S1A**). Percent viability was determined by normalizing the average well-level cell counts for the infected control (**Supplementary Figure S1B**). We found that niclosamide has potent 50% maximal inhibition (IC_{50}) values of 564 nM for VeroE6 and 261 nM for H1437. However, niclosamide caused a 50% reduction in cell viability (CC_{50}) at concentrations of 1050 nM and 438 nM for VeroE6 and H1437, respectively, resulting in poor selectivity indices in both cell lines (1.86 for VeroE6 and 1.67 for H1437). The concentration-response curves for this experiment are shown in **Figure 1B** along with representative images for infected control, mock, and 10 μ M niclosamide conditions for each cell line. As illustrated in **Figure 2B** and **Supplementary Figure 1A**, the average percentage of N protein-positive cells in untreated infected controls after 48 hours of infection was significantly higher in VeroE6 (69 %) than H1437 (9%) indicating more efficient cell-to-cell spread in the former. In conclusion, niclosamide has a low SI in two cell lines of fibroblast origin, representing a liability for therapeutic use.

Niclosamide potency is SARS-CoV-2 variant dependent

Niclosamide has a complex polypharmacology profile against host-cell pathways, which may contribute to the antiviral efficacy and/or cytotoxicity of the compound and lead to variable responses across SARS-CoV-2 VOCs that rely differentially on these pathways. To evaluate the antiviral efficacy of niclosamide against VOCs, we used a modified infection assay in VeroE6. Exposure to niclosamide was reduced to a 1- hour preincubation and the assay window was shortened to 24 hours post-infection (**Figure 2A**) to limit compound toxicity. VeroE6 cells were used as they demonstrated a higher N-protein positivity rate than H1437 cells. We evaluated the antiviral activity of niclosamide against the WA1 (wildtype), B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta) variants in 10-point, 2-fold dilution. 10-Point dose-response efficacy experiments showed niclosamide had statistically significant differences in efficacy against VOCs, was most potent against the B.1.1.7 strain ($IC_{50} = 298$ nM), and least potent against the WA1 strain ($IC_{50} = 1664$ nM). The full efficacy data for all variants are shown in **Figures 2B-C**. The CC_{50} for niclosamide in this shortened assay was > 10 μ M (not shown). These data demonstrate variant dependent antiviral efficacy of niclosamide.

High-content analysis suggests inhibition of entry and syncytia formation

Cell morphologic analysis of cells infected with VOCs, under the treatment of niclosamide, revealed several defining characteristics of infection influenced by compound treatment. We quantified these observations using morphological cell profiling analysis. We used data (B.1.1.7 variant in VeroE6) from the viral control (mock) and three different efficacious concentrations of niclosamide around its IC_{50} (156 nM, 313 nM, 625 nM) to reanalyze using a more extensive analysis pipeline that included intensity and area/shape measurements for both nuclear and viral

channels. For this analysis, syncytia/individually infected cells were defined as “viral objects.” We determined that treatment with niclosamide decreased the maximum size of syncytia (**Figure 3A**) consistent with an inhibition of cell-to-cell spread. We also found that treatment reduced the number of individually infected cells within a well (**Figure 3B**) consistent with an inhibition of viral entry. Finally, we found that the N protein intensity of remaining viral objects increased with escalating concentrations of niclosamide (**Figure 3C**). The combination of these observations suggests multiple MOA including inhibition of viral entry and cell-to-cell spread resulting in fewer infected cells with dramatically increased cellular viral N protein content. These results provide support for the polypharmacology of niclosamide that contributes to multimodal efficacy against SARS-CoV-2. In addition, these results suggest that niclosamide may not directly inhibit viral replication *in vitro*.

Structure-activity relationship of niclosamide analogs versus SARS-CoV-2 infection

Efficacy and cytotoxicity of 33 previously designed analogs³⁸ of niclosamide were used to establish a preliminary structure-activity relationship (SAR) profile for niclosamide for anti-SARS-CoV-2 activity in VeroE6 and H1437 cell lines. These analogs were also salicylanilides and had substituent modifications on the nitroaniline and/or chlorosalicyl rings (**Figure 4A**) intending to improve the selectivity while maintaining antiviral efficacy. Analog structures are shown in **Supplementary Figure S2**. Analogs were evaluated using the assay described in **Figure 1A**. All analogs were tested in 10-point 2-fold dilution series (N=3) from a starting concentration of 20 μ M. VeroE6 analog screening was performed using the B.1.1.7 variant at an MOI of 0.1, while H1437 screening was performed using the WA1 variant at an MOI of 1. The results from compound testing are summarized in **Table 1**, which includes IC₅₀ and CC₅₀ values for both cell lines. As shown in Table 1, we found that 14 analogs retained IC₅₀ values in the

nanomolar or micromolar range in VeroE6, while seven (compounds 2, 3, 4, 11, 12, 24, 34) were efficacious in both VeroE6 and H1437. Four compounds (2, 7, 11, 24) showed improved potency and reduced cytotoxicity against VeroE6 compared to niclosamide (**Figure 4C-F**). Overall, improvements in cytotoxicity were less pronounced against H1437. Notably, the variant dependent potency difference was conserved in H1437 cells and was significantly less potent against WA1 ($IC_{50} = 16770$ nM) than B.1.1.7 ($IC_{50} = 261$ nM), consistent with results in VeroE6 cells.

In general, we found that the replacement of the nitro group on the nitroaniline ring was well tolerated (compounds 5, 6, 7, 10, 24 and 34) and improved the selectivity index. We also noted that modification to the chloro position on the salicylic acid ring (R2) was well tolerated and all compounds with only this modification retained antiviral efficacy (compounds 2, 3, 4, 11, 12). Many analogs (compounds 7,8, 10, 14-19, 22, 25, 28-30, and 33) were found to exacerbate infection in H1437 cells (**Supplementary Figure S3**) and showed inverted concentration-response curves at high concentrations. Remarkably, the removal of the hydroxyl group (R1) on the salicylic acid ring (compound 9) resulted in a complete loss of activity in both VeroE6 and H1437 (**Figure 5A**). This hydroxyl group has been previously reported as the protonophore responsible for the mitochondrial uncoupling activity of niclosamide^{23,38}.

Given the drastic loss of activity, we evaluated the anti-SARS-CoV-2 efficacy of other protonophore mitochondrial uncouplers including FCCP³⁹, 2,4 DNP⁴⁰, oxyclozanide⁴¹ and dicumarol⁴². These compounds were evaluated against WA1 and B.1.1.7 variants in VeroE6 cells using the 24-hour infection conditions described in **Figure 3A**. Both FCCP and oxyclozanide showed efficacy in the micromolar range (**Figure 5B-F**). The potency of these compounds was higher against B.1.1.7 than WA1, however the difference was more pronounced for niclosamide.

These results indicate that the mechanism of action for niclosamide against SARS-CoV-2 is at least partially due to its physiochemical property as a protonophore, implicating energetic stress response pathways in SARS-CoV-2 infection.

Discussion

There remains an urgent need for COVID-19 therapeutics, which can be used to prevent or treat the spread of the virus SARS-CoV-2. The FDA approved oral anthelmintic drug niclosamide has antiviral activity against SARS-CoV-2 infection *in vitro* and *in vivo*⁴³, which has generated interest in its application for the treatment of COVID-19 and resulted in the conductance of several human clinical trials. However, given its high cytotoxicity, unknown efficacy against SARS-CoV-2 variants, low systemic bioavailability, and significant polypharmacology, we were hesitant to consider niclosamide as a promising antiviral option. In this study, we used high-content imaging of SARS-CoV-2 infected cells to evaluate some of the limitations of niclosamide as a COVID-19 antiviral. We also extended our studies to structural analogs of niclosamide, intending to reveal a preliminary structure-activity relationship profile that could be used for future compound development.

Niclosamide has potent cytotoxic/cytostatic effects when applied directly to cells *in vitro*³⁴, suggesting that it may have high acute toxicity *in vivo* with increased systemic exposure. Clinically, the cytotoxicity is limited by the poor bioavailability of niclosamide, which has low systemic exposure. To evaluate niclosamide toxicity, we used high-content fluorescence imaging to determine a selectivity index for niclosamide in two different cell models including VeroE6 and the more physiologically relevant human lung adenocarcinoma cell line H1437. We found that niclosamide has a very poor selectivity index in both cell lines (SI <2) after 72 hours of compound exposure, suggesting that it would likely have a small therapeutic window clinically

even if the compound exposure was high enough in the lungs for antiviral efficacy. Longer durations of exposure to niclosamide at relevant antiviral concentrations are likely to cause significant side effects, which limits clinical application. Further studies are needed to evaluate the safety of niclosamide at antiviral concentrations *in vivo*.

Our results are consistent with the results from recent clinical studies of niclosamide. Since it was identified as an anti-SARS-CoV-2 agent *in vitro*, there have been several clinical studies to evaluate the antiviral efficacy and safety of niclosamide. Notably, a recent phase 2 clinical trial using 2g of orally administered niclosamide for 7 days revealed no statistically significant effect on the duration of the contagious period of SARS-CoV-2⁴⁴. While niclosamide was well tolerated in this trial, the low efficacy and low adverse event rate are likely because the systemic exposure is lower than what is required to observe antiviral activity or compound-related toxicity. To address the poor oral bioavailability, several different formulations have been developed for niclosamide to improve its exposure to the necessary site of action^{45,46}. This has included a formulation as an inhalable/intranasal powder to increase compound exposure in the lungs. Unfortunately, a recent phase-1 safety trial using 50 mg over 2.5 days of inhalable/intranasal niclosamide revealed moderate lung irritation in 59% of participants, which suggests compound-related toxicity may be playing a significant role at higher local concentrations in the lungs⁴⁷. Although niclosamide is generally well-tolerated when used as an anthelmintic drug, this is because it has low bioavailability, poor solubility, and stays within the GI tract with very low systemic exposure.

A further limitation for using niclosamide as a COVID-19 therapeutic is its unknown efficacy against the different emerging SARS-CoV-2 VOCs. We determined the efficacy for niclosamide against the WA1 (wildtype), B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta)

variants in VeroE6 cells. We found that there were significant differences in potency ranging from 298 nM (beta variant) to 1664 nM (wildtype). Interestingly, the trend in potency correlates with the ACE2 binding affinity for the different variants⁴⁸. Variants, including alpha and beta, also have higher fusogenicity than the wildtype variant and are more likely to undergo cell-to-cell spread by syncytia³⁵, which may help explain the differences in potency.

These results are in contrast with those reported by Weiss *et al.*, which showed no significant difference in potency amongst variants⁴⁹. However, their study used qRT-PCR of viral RNA to determine IC₅₀ values, which is far less sensitive than a high-content imaging approach and does not provide information on the clinically relevant endpoint of cell-to-cell spread inhibition. Given the differences in potency amongst SARS-CoV-2 variants of concern, there arises a concern for the rapid development or selection of resistant strains that do not respond to niclosamide treatment. While the emergence of drug resistance is possible for any mechanism of action inhibiting SARS-CoV-2, the pronounced difference between niclosamide's efficacy amongst the VOCs makes niclosamide resistance inexorable. Further studies to understand the mechanistic differences underlying variant-dependent responses to drugs like niclosamide may ultimately inform *de novo* drug development for COVID-19.

To understand the MOA, we used morphological profiling of B.1.1.7 infected VeroE6 cells to evaluate the effect of niclosamide treatment on SARS-CoV-2 infection. We found that niclosamide inhibits the spread of virus to adjacent cells in a concentration-dependent fashion as indicated by the reduction in size of viral syncytia. We also observed that the total number of viral objects (individually infected cells or syncytia) decreased with niclosamide treatment, which is consistent with entry inhibition. For example, if niclosamide were only influencing cell-to-cell spread, the total number of viral objects would remain constant and only the size of the

syncytia would be affected. While the complete mechanism of action for niclosamide is complex, our results suggest that both inhibition of cell-to-cell spread and entry inhibition play a role in its activity (**Figure 6**). The degree to which each of the MOAs contributes to efficacy may be different for SARS-CoV-2 variants, which could help explain the differences in potency.

The polypharmacology of niclosamide is a major issue for its utility as a COVID-19 antiviral. Niclosamide is known to influence many different signal transduction pathways and has been implicated in the treatment of a wide range of diseases including several cancers, bacterial infections, viral infections, type 2 diabetes, non-alcoholic fatty liver disease, rheumatoid arthritis, and others. Unfortunately, the mechanism of action for niclosamide remains elusive for the majority of its biological effects. It is often unclear if there is a direct interaction between niclosamide and a molecular target, or if there is an indirect mechanism of action at play²¹. An underlying mechanism for its broad activity may be its ability to act as a protonophore, which has many different downstream effects in cells including disruption of pH gradients, mitochondrial uncoupling, and transcriptional modulation of various gene targets²¹. This mechanistic ambiguity also translates to its antiviral efficacy. It is likely that the antiviral activities of niclosamide (e.g., inhibition of entry, replication, and syncytia formation) are all downstream consequences of its activity as a nonspecific protonophore since activity was lost following removal of the hydroxyl group. If this is the case, then it may be challenging to separate the undesired off-target effects from the antiviral effects. While our studies suggest that niclosamide and other mitochondrial uncouplers demonstrate anti-SARS-CoV-2 efficacy, further studies are warranted to determine if these mechanisms of action are unified by protonophore activity.

While niclosamide is not an ideal candidate itself, it may represent a promising chemical tool for the development of more specific SARS-CoV-2 inhibitors. In particular, inhibition of cell-to-cell spread by syncytia is an extremely attractive mechanism for inhibition. Syncytia, which are multinucleated bodies resulting from the fusion of adjacent cells, are a key characteristic of SARS-CoV-2 infection and have been observed in many post-mortem histological samples from fatal COVID-19 cases^{28,50}. Syncytia formation facilitates the rapid spread of the viral genome between cells⁵¹, which increases the area of infected tissue and may enhance immune system evasion⁵². An inhibitor of cell-to-cell infection like niclosamide may be clinically useful for the treatment or prevention of COVID-19, especially when cocktailed with other direct acting antivirals.

In this study, we also tested the antiviral efficacy of 33 structural analogs of niclosamide to establish a preliminary structure-activity relationship profile which could aid in the development of compounds with antiviral efficacy and less off-target effects. We identified seven compounds (compounds 2, 3, 4, 11, 12, 24, 34) that were efficacious in both VeroE6 and H1437 cell models and four of which had improved potency and reduced cytotoxicity in VeroE6 (Compounds 2,7,11 and 24). Consequently, we believe there is a potential for designing better niclosamide analogs with improved properties. Additionally, our structure-activity analysis revealed some mechanistic features of niclosamide. Most noteworthy, the removal of the protonophore hydroxyl group resulted in complete loss of activity in both cell models. The efficacy of analogs strongly relied on their weakly acidic and lipophilic nature. Analogs with higher predicted acidity (pKa) due to the presence of carboxylic acid substituents were generally completely inactive. We also determined that other protonophores, including FCCP and oxyclozanide, also had anti-SARS-CoV-2 efficacy, suggesting that the ability to disrupt pH gradients is central to

the mechanism of action for niclosamide. Niclosamide has been shown to neutralize endo-lysosomal pH gradients, which is believed to be responsible for its broad-spectrum antiviral activity²⁴. Our results indicate that this nonspecific mechanism of action also significantly contributes to the activity of niclosamide against SARS-CoV-2.

Overall, the poor selectivity index, low bioavailability, complex polypharmacology, nonspecific protonophore activity, and variant-dependent potency of niclosamide limit its potential as a COVID-19 therapeutic. However, our studies have shown that changes to the salicyl and aniline rings can modulate selectivity and bioavailability while maintaining its activity. Therefore, niclosamide represents a useful chemical probe that can be leveraged in a large-scale SAR campaign to design better analogs in the future.

Methods

Compounds

Niclosamide, FCCP, 2,4 DNP, Oxyclozanide and Dicumarol were obtained from Sigma Aldrich and prepared as 10 mM stock solutions in dimethylsulfoxide (DMSO). The 33 structural analogs of niclosamide were obtained from previous studies³⁸. Compounds were solubilized at 10 mM in DMSO, and were dispensed onto cells using an HPD300e digital compound dispenser.

Cells and Virus

VeroE6 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM), and H1437 cells were maintained in RPMI 1640 base medium. Both cell lines were supplemented with 10% fetal bovine serum (FBS) and 1X pen-strep solution and were grown at 37°C with 5% CO₂ following standard cell culture procedures. These cell lines were tested for mycoplasma contamination

before use and were negative. The following reagents were deposited by the Centers for Disease Control and Prevention and were obtained through BEI resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281, USA/CA_CDC_5574/2020 (B.1.1.7), NR-54011, USA/MD-HP01542/2021 (Lineage B.1.351), NR-55282, Japan/TY7-503/2021 (Brazil P.1), NR-54982, USA/PHC658/2021 (Lineage B.1.617.2), NR-55611. Viral stocks were grown in VeroE6 and titers were determined by TCID₅₀ using the Reed and Muench method⁵³. All the work with live SARS-CoV-2 virus was performed in biosafety level-3 containment lab (BSL3) with the approval of the University of Michigan's Department of Environment and Health and Safety and the Institutional Biosafety Committee.

Anti-SARS-CoV-2 high content bioassays

Assays were adapted from previous work and optimized for H1437 and VeroE6 cell lines^{17,54}. For 48-hour infection experiments, VeroE6 and H1437 cells were seeded onto 384 well plates (6057300, Perkin Elmer) at densities of 3000 and 5000 cells per well, respectively, in 50 μ L of media. After 24 hours of cell attachment at 37°C and 5% CO₂, compounds were dispensed directly to the cell plates using an HPD300e digital compound dispenser. All wells were normalized to a constant DMSO concentration of 0.2%, and plates contained both infected and uninfected control wells. After 24 hours of preincubation with compounds, cells were inoculated with the indicated SARS-CoV-2 variant at MOIs of 0.1 for VeroE6 and 1 for H1437. Cells were incubated with virus and compounds for an additional 48 hours and then fixed with 4% paraformaldehyde for 30 minutes at room temperature. Cells were then permeabilized with 0.3% Triton-X100 for 15 minutes and stained with anti-nucleocapsid protein primary antibody (ABIN6952432, Antibodies Online) at a dilution of 1:2000 overnight at +4°C. Following primary antibody staining, cells were stained with a dye cocktail containing 1:1000 secondary

antibody Alexa-647 (goat anti-mouse, A21235, Thermo Fisher) and 10 µg/mL Hoechst 33342 pentahydrate (bis-benzimide) for nuclear labeling for a total of 30 minutes at room temperature. Cells were stored in PBS before imaging. For 24-hour infection experiments, the methods were comparable except that VeroE6 cells were seeded at 5000 cells per well, compounds were preincubated for 1 hour instead of 24, and the infection window was 24 hours instead of 48. All other inoculation, fixation and staining procedures were identical.

High Content Imaging

Stained assay plates were imaged using both a Thermo Fisher CX5 with a 10X/0.45NA objective lens and a Yokogawa Cell Voyager 8000 (CV8000) microscope with a 20X/1.0NA water immersion lens. Imaging techniques were followed as described previously for detection of nuclei and SARS-CoV-2 nucleocapsid protein^{17,54}. A total of N=9 fields per well were imaged for all assay plates, accounting for roughly 80% of the total well area.

Image Processing

Images were processed using the image segmentation and analysis software CellProfiler 4.0⁵⁵. Separate pipelines were developed for H1437 and VeroE6 images. Pipelines were used to identify nuclei (Hoechst 33342) and viral objects including multinucleated syncytia and individually infected cells (Alexa Fluor 647) by adaptive otsu thresholding. Similar to previous work, infected cells were identified using the *relateobjects* module whereby any nucleus contained within a viral object was defined as infected⁵⁴. For morphological profiling of B.1.1.7 infection vs. niclosamide in VeroE6, additional intensity, textural and spatial features were measured using CellProfiler 4.0 for both the nuclear and viral channels.

Concentration response analysis and IC₅₀/CC₅₀ determination

Field level data were grouped at the well level using Knime⁵⁶ and used to determine normalized percent infection and percent viability scores. Raw percent infection per well was determined by taking the ratio of infected nuclei to total nuclei and multiplying by 100. Normalized percent infection was then generated such that “100% infection” was equivalent to the average raw percent infection of the viral control for each plate. Cell counts for the entire plate were normalized and 100% viability was based on the average cell count of the infected DMSO control wells. Concentration-response curves were plotted in GraphPad Prism 9.0 (GraphPad Software) and fitted using a semi-log 4-parameter variable slope model. IC₅₀ and CC₅₀ values were extracted from percent infection curves and percent viability curves, respectively. Selectivity indices were determined by taking a ratio of the CC₅₀ and IC₅₀.

High content imaging analysis of B.1.1.7 infection versus niclosamide

Object level data for nuclei and viral objects (syncytia and individually infected cells) was used to evaluate morphological and phenotypic features of B.1.1.7 infection versus niclosamide including changes in N protein intensity and area of viral objects. Only images for the infected DMSO vehicle control, as well as 3 different concentrations of niclosamide (156 nM, 313 nM and 625 nM) were included in this analysis. The max viral object area reported in Figure 3A represents the largest viral object observed for each condition including all fields and replicate wells. The mean N protein intensity for infected cells was computed at the object level and the results from Figure 3C include data for cells in each condition.

Statistical analysis and hypothesis testing

All statistical analyses and hypothesis testing was performed using GraphPad Prism 9.0 (GraphPad software). Specifics for statistical analyses, including sample sizes and other important data are included within the text of figure legends.

Acknowledgements

We acknowledge funding from the University of Michigan Institute for Clinical and Health Research (MICHR; National Center for Advancing Translational Science Grant UL1TR002240) and the U-M Center for Drug Repurposing. JZS is supported by the National Institute of Diabetes and Kidney Diseases (R01DK120623). CEW is supported in part by The University of Michigan Biological Scholars Science Program. JWW is supported by an American Foundation for Pharmaceutical Education (AFPE) regional award. CM is supported by European funding MSCA actions, GA481247. SRM is supported by a pharmacological sciences training program (PSTP) T32 training grant. We thank Tracey Schultz for thoughtful discussions and assistance with cell culture. Figures were generated using Biorender.com. The authors declare no conflicts of interest.

References

1. Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. *Nature Reviews Microbiology* 2020 19:3 **19**, 141–154 (2020).
2. Aslan, A., Aslan, C., Zolbanin, N. M. & Jafari, R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. *Pneumonia* 2021 13:1 **13**, 1–15 (2021).
3. Mizrahi, B. *et al.* Longitudinal symptom dynamics of COVID-19 infection. *Nature Communications* 2020 11:1 **11**, 1–10 (2020).
4. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* **20**, 533–534 (2020).
5. Harvey, W. T. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* **19**, 409–424 (2021).

- 465 6. Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B. & Prado, E. O. SARS-CoV-2
466 vaccines strategies: a comprehensive review of phase 3 candidates. *npj Vaccines* 2021 6:1 **6**, 1–17
467 (2021).
- 468 7. Cully, M. A tale of two antiviral targets - and the COVID-19 drugs that bind them. *Nat Rev Drug*
469 *Discov* **21**, 3–5 (2022).
- 470 8. Whitley, R. Molnupiravir — A Step toward Orally Bioavailable Therapies for Covid-19. *New*
471 *England Journal of Medicine* **386**, 592–593 (2022).
- 472 9. Hammond, J. *et al.* Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *New*
473 *England Journal of Medicine* **386**, 1397–1408 (2022).
- 474 10. Feinmann, J. Covid-19: global vaccine production is a mess and shortages are down to more than
475 just hoarding. *BMJ* **375**, (2021).
- 476 11. Qomara, W. F., Pramanissa, D. N., Amalia, S. H., Purwadi, F. v. & Zakiyah, N. Effectiveness of
477 Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.
478 *Int J Gen Med* **14**, 8557–8571 (2021).
- 479 12. Gottlieb, R. L. *et al.* Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *N*
480 *Engl J Med* **386**, 305–315 (2022).
- 481 13. Chen, R. E. *et al.* Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-
482 derived polyclonal antibodies. *Nature Medicine* 2021 27:4 **27**, 717–726 (2021).
- 483 14. Takashita, E. *et al.* Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
484 *New England Journal of Medicine* **386**, 1475–1477 (2022).
- 485 15. Pushpakom, S. *et al.* Drug repurposing: progress, challenges and recommendations. *Nature*
486 *Reviews Drug Discovery* 2018 18:1 **18**, 41–58 (2018).
- 487 16. Drayman, N. *et al.* Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-
488 CoV-2. *Science* (1979) **373**, 931–936 (2021).
- 489 17. Mirabelli, C. *et al.* Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing
490 candidates for COVID-19. *Proc Natl Acad Sci U S A* **118**, (2021).
- 491 18. Touret, F. *et al.* In vitro screening of a FDA approved chemical library reveals potential inhibitors
492 of SARS-CoV-2 replication. *Scientific Reports* **10**, 13093 (2020).
- 493 19. Xiao, X. *et al.* Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-
494 CoV-2. *Frontiers in Immunology* **11**, (2020).
- 495 20. Jeon, S. *et al.* Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved
496 drugs. *Antimicrobial Agents and Chemotherapy* **64**, (2020).
- 497 21. Chen, W., Mook, R. A., Premont, R. T. & Wang, J. Niclosamide: Beyond an antihelminthic drug.
498 *Cellular Signalling* **41**, 89–96 (2018).

- 499 22. Fonseca, B. D. *et al.* Structure-activity analysis of niclosamide reveals potential role for
500 cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. *J*
501 *Biol Chem* **287**, 17530–17545 (2012).
- 502 23. Kumar, R. *et al.* Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-
503 defective cancers. *Nature Communications* 2018 9:1 **9**, 1–13 (2018).
- 504 24. Jurgeit, A. *et al.* Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad
505 Antiviral Effects. *PLoS Pathogens* **8**, 1002976 (2012).
- 506 25. Wu, C. J. *et al.* Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by
507 Niclosamide. *Antimicrobial Agents and Chemotherapy* **48**, 2693 (2004).
- 508 26. Prabhakara, C. *et al.* Strategies to target SARS-CoV-2 entry and infection using dual mechanisms
509 of inhibition by acidification inhibitors. *PLOS Pathogens* **17**, e1009706 (2021).
- 510 27. Gassen, N. C. *et al.* SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers
511 host-targeting antivirals. *Nature Communications* 2021 12:1 **12**, 1–15 (2021).
- 512 28. Braga, L. *et al.* Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.
513 *Nature* 2021 594:7861 **594**, 88–93 (2021).
- 514 29. Lin, C. K. *et al.* Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian
515 cancer. *Oncotarget* **7**, 8993 (2016).
- 516 30. Fan, X., Li, H., Ding, X. & Zhang, Q. Y. Contributions of Hepatic and Intestinal Metabolism to the
517 Disposition of Niclosamide, a Repurposed Drug with Poor Bioavailability. *Drug Metab Dispos* **47**,
518 756–763 (2019).
- 519 31. Chang, Y. W. *et al.* Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats.
520 *Journal of Food and Drug Analysis* **14**, 15 (2020).
- 521 32. Reddy, A. S. & Zhang, S. Polypharmacology: drug discovery for the future. *Expert Rev Clin*
522 *Pharmacol* **6**, 41–47 (2013).
- 523 33. Wieland, A. *et al.* Anticancer effects of niclosamide in human glioblastoma. *Clin Cancer Res* **19**,
524 4124–4136 (2013).
- 525 34. Hamdoun, S., Jung, P. & Efferth, T. Drug repurposing of the anthelmintic niclosamide to treat
526 multidrug-resistant leukemia. *Frontiers in Pharmacology* **8**, (2017).
- 527 35. Rajah, M. M. *et al.* SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated
528 syncytia formation. *EMBO J* **40**, (2021).
- 529 36. Saito, A. *et al.* Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
530 *Nature* **602**, 300–306 (2022).
- 531 37. Zhang, Y. *et al.* SARS-CoV-2 spike L452R mutation increases Omicron variant fusogenicity and
532 infectivity as well as host glycolysis. *Signal Transduction and Targeted Therapy* 2022 7:1 **7**, 1–3
533 (2022).

- 534 38. Bhagat, H. A. *et al.* N-substituted phenylbenzamides of the niclosamide chemotype attenuate
535 obesity related changes in high fat diet fed mice. *PLOS ONE* **13**, e0204605 (2018).
- 536 39. Park, K. S. *et al.* FCCP depolarizes plasma membrane potential by activating proton and Na⁺
537 currents in bovine aortic endothelial cells. *Pflugers Archiv : European journal of physiology* **443**,
538 344–352 (2002).
- 539 40. Blaikie, F. H. *et al.* Targeting dinitrophenol to mitochondria: limitations to the development of a
540 self-limiting mitochondrial protonophore. *Biosci Rep* **26**, 231–243 (2006).
- 541 41. Shrestha, R., Johnson, E. & Byrne, F. L. Exploring the therapeutic potential of mitochondrial
542 uncouplers in cancer. *Molecular Metabolism* **51**, 101222 (2021).
- 543 42. Kotova, E. A. & Antonenko, Y. N. Fifty Years of Research on Protonophores: Mitochondrial
544 Uncoupling As a Basis for Therapeutic Action. *Acta Naturae* **14**, 4 (2022).
- 545 43. Blake, S. *et al.* Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of
546 Inflammatory Cytokines in a Rodent Model. *ACS Infectious Diseases* **7**, 2229–2237 (2021).
- 547 44. Cairns, D. M. *et al.* Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance,
548 Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A
549 Phase 2 Randomized Clinical Trial. *JAMA Network Open* **5**, e2144942–e2144942 (2022).
- 550 45. Parikh, M. *et al.* Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men
551 with castration-resistant prostate cancer. *Scientific Reports* **2021 11:1** **11**, 1–7 (2021).
- 552 46. Lin, C. K. *et al.* Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian
553 cancer. *Oncotarget* **7**, 8993 (2016).
- 554 47. Backer, V. *et al.* A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and
555 intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19. *The*
556 *Lancet Regional Health - Europe* **4**, 100084 (2021).
- 557 48. Liu, H., Wei, P., Kappler, J. W., Marrack, P. & Zhang, G. SARS-CoV-2 Variants of Concern and
558 Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. *Frontiers in*
559 *Immunology* **13**, 50 (2022).
- 560 49. Weiss, A. *et al.* Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-
561 2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant
562 (B.1.617.2). *PLOS ONE* **16**, e0260958 (2021).
- 563 50. Bussani, R. *et al.* Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of
564 advanced COVID-19 pathology. *EBioMedicine* **61**, (2020).
- 565 51. Lin, L., Li, Q., Wang, Y. & Shi, Y. Syncytia formation during SARS-CoV-2 lung infection: a disastrous
566 unity to eliminate lymphocytes. *Cell Death & Differentiation* **2021 28:6** **28**, 2019–2021 (2021).
- 567 52. Rajah, M. M., Bernier, A., Buchrieser, J. & Schwartz, O. The Mechanism and Consequences of
568 SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. *Journal of Molecular Biology* **434**,
569 167280 (2022).

53. Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. *American Journal of Epidemiology* **27**, 493–497 (1938).
54. Wotring, J. W., Fursmidt, R., Ward, L. & Sexton, J. Z. Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern. *J Dairy Sci* **105**, 2791–2802 (2022).
55. McQuin, C. *et al.* CellProfiler 3.0: Next-generation image processing for biology. *PLOS Biology* **16**, e2005970 (2018).
56. Berthold, M. R. *et al.* KNIME - the Konstanz information miner. *ACM SIGKDD Explorations Newsletter* 58–61 (2009) doi:10.1145/1656274.1656280.

600 **pageFigures**




Figure 1. Niclosamide is toxic at antiviral concentrations after long term exposure. A.)

Workflow for high content anti-SARS-CoV-2 bioassay screening to determine infection inhibition and cytotoxicity. B.) 10-point, 2-fold dilution concentration-response curves for VeroE6 and H1437 cells with a starting concentration of 10 μM. VeroE6 cells were infected with SARS-CoV-2 B.1.1.7 variant at a multiplicity of infection (MOI) of 0.1, while H1437 were infected with SARS-CoV-2 WA1 variant at an MOI =1 to achieve optimal infection at 48 hours post-infection. Data points represent mean ± SEM for N=10 replicates per condition. Curve fitting was performed in GraphPad Prism 9.0 using a semi-log 4-parameter variable slope model. Representative overlay images for mock, vehicle, and 10 μM Niclosamide treatment (infected) are included (cyan = nuclei, magenta = SARS-CoV-2 N protein).




Figure 2. Niclosamide potency is SARS-CoV-2 variant dependent. A.) Assay timeline for 24-hour infection experiment. The assay window was shortened to reduce niclosamide toxicity. B.) 10-point 2-fold concentration-response curves for niclosamide against the different SARS-CoV-2 variants of concern (MOI = 0.1 for each variant) with a top concentration of 10 μ M. Curves were fitted with GraphPad Prism 9.0 software using a semi-log 4-parameter variable slope model. Data for each variant was normalized to the average percent infected of its respective viral control. Data points represent mean $\pm$ SEM for N=3 replicates. C.) IC₅₀ values for niclosamide potency against SARS-CoV-2 variants of concern. Values were extracted from curve fitting using GraphPad 9.0 and include SEM error bars (WA1: 1664 $\pm$ 149 nM, B.1.1.7: 298 $\pm$ 23 nM, B.1.351: 440 $\pm$ 21 nM, B.1.617.2: 774 $\pm$ 58 nM, P.1: 399 $\pm$ 34 nM). Significance was determined using Student's T-tests (* = P<0.05, ** = P<0.01).




Figure 3. Morphological profiling of B.1.1.7 infection versus niclosamide treatment in VeroE6. Image analysis reveals mechanistic characteristics of niclosamide activity against SARS-CoV-2 infection. A.) The maximum area of viral objects decreases with increasing niclosamide concentration. Data is the max area for viral objects in each condition. Viral control: N=17452, +156 nM niclosamide: N=2425, +313 nM niclosamide: N= 1470, +625 nM niclosamide: N= 496. B.) Viral objects per well decreases with increasing niclosamide concentration. Viral objects include single infected cells and syncytia. Replicate values are indicated on the X axis. C.) Mean pixel intensity for viral objects in each condition. Pixel intensity increases with increasing niclosamide concentration. D.) Representative images for each condition including N-protein channel, nuclear channel, an overlaid image and a fire lookup table (LUT) image of the N-protein channel. Images were taken on a CX5 high content microscope at 10X magnification. * = $P < 0.05$, *** = $P < 0.001$, **** = $P < 0.0001$.




Figure 4. Niclosamide analogs have improved efficacy and reduced cytotoxicity in VeroE6.

A.) Structure of niclosamide indicating the chlorosalicyl/nitroaniline rings, and analog scaffold with modified substituent positions labeled. B.) IC₅₀ vs. CC₅₀ plot highlighting efficacious compounds in VeroE6. Compounds with improved potency and cytotoxicity profiles are circled on the plot. C.) 10-point, 2-fold concentration-response curves for the top four niclosamide analogs with a starting concentration of 20 μM. Data are shown as the mean ± SEM of N=3 replicate wells per condition. Curves for infection (in red) and cell viability (in black) are included. D.) Representative images of infected cells treated with indicated compounds and viral control (Vehicle). (10X magnification, Cyan = nuclei, magenta = SARS-CoV-2 nucleocapsid protein).




Figure 5. Efficacy of protonophores against SARS-CoV-2. A.) Removal of protonophore hydroxyl of niclosamide results in a complete loss of efficacy in both VeroE6 and H1437 cells. B.) Chemical structures for other protonophores evaluated against SARS-CoV-2 infection. C-D.) 10-point, 2-fold concentration response curves for protonophores versus WA1 variant (C.) and B.1.1.7 variant (D.) with starting concentrations of 100 μM. E.) IC₅₀ plot for antiviral protonophores indicating significantly different potency against variants. F.) Table of IC₅₀ and CC₅₀ values for protonophores.




Figure 6. Diagram of niclosamides effect on SARS-CoV-2 entry and spike protein-mediated syncytia formation. 1.) SARS-CoV-2 binds to the ACE2 receptor of the host cell and enters. Niclosamide has been shown to inhibit this entry step *in vitro* 2.) Viral replication generates many copies of the RNA genome. 3.) Infection results in an increased expression of viral spike (S) protein and host cell TMEM16F at the plasma membrane. 4.) The S protein at the surface on an infected cell binds to the ACE2 receptor of an adjacent uninfected cell. 5.) Spike-dependent syncytia formation is mediated by the calcium-dependent lipid scramblase TMEM16F to generate multinucleated infected cell bodies. Niclosamide, an inhibitor of TMEM16F, has been shown to block spike-dependent syncytia formation.

686 Tables

687 **Table 1. SAR table for Niclosamide Analogs.** IC₅₀ and CC₅₀ values for VeroE6 (SARS-CoV-2
688 B.1.1.7 variant) and H1437 (SARS-CoV-2 WA1 variant). Physical properties including cLogP,
689 pKa and logS were calculated using MOE and included in the table for each compound.
690 Compounds that have efficacy against both cell lines are highlighted in gray.

Compound #	R1	R2	R3	R4	R5	R6	R7	Vero-E6 (B.1.1.7)		H1437 (WA1)		cLogP	pKa	logS
								IC ₅₀ (nM)	CC ₅₀ (nM)	IC ₅₀ (nM)	CC ₅₀ (nM)			
1 (Niclosamide)	OH	Cl	H	Cl	H	NO ₂	H	564	1050	16770	17060	4.17	7.98	-5.00
2	OH	H	H	Cl	H	NO ₂	H	296	5590	4915	8403	3.47	7.52	-4.32
3	OH	CH ₃	H	Cl	H	NO ₂	H	1254	6277	2595	3056	3.97	7.52	-4.66
4	OH	OCH ₃	H	Cl	H	NO ₂	H	1769	10110	10880	8941	3.39	7.65	-4.39
5	OH	Cl	H	Cl	H	H	H	890	8435	>20000	18570	4.17	8.01	-4.54
6	OH	Cl	H	Cl	H	CH ₃	H	760	4591	>20000	6048	4.66	8.01	-4.88
7	OH	Cl	H	Cl	H	COOCH ₃	H	334	8142	Inverted	>20000	4.15	7.98	-4.94
8	OH	Cl	H	Cl	H	COOH	H	>20000	>20000	Inverted	>20000	3.67	4.03	-4.54
9	H	Cl	H	Cl	H	NO ₂	H	>20000	>20000	>20000	>20000	4.63	14	-5.27
10	OH	Cl	H	Cl	H	OCH ₃	H	4248	>20000	Inverted	18900	4.05	8.02	-4.59
11	OH	t-Bu	H	Cl	H	NO ₂	H	423	3407	3097	1921	5.50	7.51	-5.68
12	OH	OCH ₃	H	Cl	H	NO ₂	H	1498	10290	16880	7529	3.39	7.65	-4.39
13	OH	t-Bu	H	Cl	H	COOCH ₃	H	>20000	14570	>20000	>20000	5.49	7.50	-5.62
14	OH	t-Bu	H	Cl	H	COOH	H	>20000	14250	Inverted	>20000	5.00	4.93	-5.22
15	OH	t-Bu	H	F	H	COOH	H	>20000	>20000	Inverted	>20000	4.41	4.73	-4.69
16	OH	t-Bu	H	CH ₃	H	COOH	H	>20000	>20000	Inverted	>20000	4.49	4.95	-4.74
17	OH	t-Bu	H	Cl	H	H	COOH	>20000	>20000	Inverted	>20000	5.00	4.93	-5.22
18	OH	t-Bu	t-Bu	Cl	H	CH ₃ SO ₂ N	H	>20000	>20000	Inverted	>20000	5.98	7.02	-6.39
19	OH	t-Bu	t-Bu	Cl	H	NH ₂	H	>20000	17590	Inverted	>20000	6.58	7.57	-6.14
20	OH	t-Bu	t-Bu	H	CH ₃	COOH	H	>20000	>20000	>20000	>20000	6.52	4.96	-6.10
21	OH	Cy	H	Cl	H	COOCH ₃	H	9910	>20000	>20000	>20000	5.96	7.50	-6.66
22	OH	Cy	H	Cl	H	COOH	H	4511	>20000	Inverted	>20000	5.48	4.93	-6.26
23	OH	CF ₃	H	CH ₃	H	COOCH ₃	H	>20000	>20000	>20000	>20000	4.97	7.49	-5.15
24	OH	Cl	H	Cl	H	CN	H	348	4720	1070	880	4.27	8.00	-5.03
25	OH	H	t-Bu	Cl	H	COOCH ₃	H	>20000	>20000	Inverted	>20000	5.22	7.52	-5.52
26	OH	t-Bu	t-Bu	Cl	H	COOH	H	>20000	>20000	>20000	>20000	6.77	4.93	-6.48
27	OH	t-Bu	t-Bu	Cl	H	COOCH ₃	H	16500	>20000	>20000	>20000	6.52	4.96	-6.10
28	OH	OCH ₃	H	CH ₃	H	COOH	H	>20000	>20000	Inverted	>20000	2.38	4.95	-3.46
29	OH	H	t-Bu	Cl	H	COOCH ₃	H	>20000	>20000	Inverted	>20000	5.22	7.52	-5.52
30	OH	H	t-Bu	Cl	H	COOH	H	>20000	>20000	Inverted	>20000	4.74	4.93	-5.12
31	OH	H	t-Bu	Cl	H	NO ₂	H	>20000	7214	>20000	1110	5.24	7.52	-5.58
32	OH	H	t-Bu	Cl	H	NH ₂	H	>20000	>20000	>20000	>20000	4.55	7.58	-4.78
33	OH	H	t-Bu	Cl	H	NSO ₂ CH ₃	H	2879	>20000	Inverted	>20000	3.95	7.03	-5.03
34	OH	Cl	H	Cl	H	Br	H	760	5473	3491	3620	4.97	8.01	-5.36

691